13 results on '"dos Santos, Daniel"'
Search Results
2. Fully automated AI-based splenic segmentation for predicting survival and estimating the risk of hepatic decompensation in TACE patients with HCC
- Author
-
Müller, Lukas, Kloeckner, Roman, Mähringer-Kunz, Aline, Stoehr, Fabian, Düber, Christoph, Arnhold, Gordon, Gairing, Simon Johannes, Foerster, Friedrich, Weinmann, Arndt, Galle, Peter Robert, Mittler, Jens, Pinto dos Santos, Daniel, and Hahn, Felix
- Published
- 2022
- Full Text
- View/download PDF
3. Quantitative washout in patients with hepatocellular carcinoma undergoing TACE: an imaging biomarker for predicting prognosis?
- Author
-
Müller, Lukas, Hahn, Felix, Jungmann, Florian, Mähringer-Kunz, Aline, Stoehr, Fabian, Halfmann, Moritz C., Pinto dos Santos, Daniel, Hinrichs, Jan, Auer, Timo A., Düber, Christoph, and Kloeckner, Roman
- Published
- 2022
- Full Text
- View/download PDF
4. Validation of the SNACOR clinical scoring system after transarterial chemoembolisation in patients with hepatocellular carcinoma
- Author
-
Mähringer-Kunz, Aline, Weinmann, Arndt, Schmidtmann, Irene, Koch, Sandra, Schotten, Sebastian, Pinto dos Santos, Daniel, Pitton, Michael Bernhard, Dueber, Christoph, Galle, Peter Robert, and Kloeckner, Roman
- Published
- 2018
- Full Text
- View/download PDF
5. Radiomics-Based Prediction of Future Portal Vein Tumor Infiltration in Patients with HCC—A Proof-of-Concept Study.
- Author
-
Stoehr, Fabian, Kloeckner, Roman, Pinto dos Santos, Daniel, Schnier, Mira, Müller, Lukas, Mähringer-Kunz, Aline, Dratsch, Thomas, Schotten, Sebastian, Weinmann, Arndt, Galle, Peter Robert, Mittler, Jens, Düber, Christoph, and Hahn, Felix
- Subjects
RETROSPECTIVE studies ,PEARSON correlation (Statistics) ,PORTAL vein ,DESCRIPTIVE statistics ,DATA analysis software ,HEPATOCELLULAR carcinoma ,LONGITUDINAL method ,DISEASE complications - Abstract
Simple Summary: Portal vein infiltration (PVI) is a complication of HCC with critical impact on further patient management as systemic therapies are recommended once PVI is diagnosed. In our study, we matched 44 patients with HCC who developed PVI in the course of disease with no CT-detectable PVI at initial diagnosis to the same number of patients who never developed PVI during follow-up, but showed the same conventional tumor traits (size and number of lesions, growth type, contrast enhancement pattern, etc.). Using LASSO regression, radiomics feature analysis showed a sensitivity and specificity of 0.78 to detect the occurrence of PVI in the validation set. Therefore, an additional radiomics evaluation at initial diagnosis could help to identify patients benefiting from a closer surveillance. Portal vein infiltration (PVI) is a typical complication of HCC. Once diagnosed, it leads to classification as BCLC C with an enormous impact on patient management, as systemic therapies are henceforth recommended. Our aim was to investigate whether radiomics analysis using imaging at initial diagnosis can predict the occurrence of PVI in the course of disease. Between 2008 and 2018, we retrospectively identified 44 patients with HCC and an in-house, multiphase CT scan at initial diagnosis who presented without CT-detectable PVI but developed it in the course of disease. Accounting for size and number of lesions, growth type, arterial enhancement pattern, Child–Pugh stage, AFP levels, and subsequent therapy, we matched 44 patients with HCC who did not develop PVI to those developing PVI in the course of disease (follow-up ended December 2021). After segmentation of the tumor at initial diagnosis and texture analysis, we used LASSO regression to find radiomics features suitable for PVI detection in this matched set. Using an 80:20 split between training and holdout validation dataset, 17 radiomics features remained in the fitted model. Applying the model to the holdout validation dataset, sensitivity to detect occurrence of PVI was 0.78 and specificity was 0.78. Radiomics feature extraction had the ability to detect aggressive HCC morphology likely to result in future PVI. An additional radiomics evaluation at initial diagnosis might be a useful tool to identify patients with HCC at risk for PVI during follow-up benefiting from a closer surveillance. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. Tumor Burden in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Head-to-Head Comparison of Current Scoring Systems.
- Author
-
Müller, Lukas, Hahn, Felix, Auer, Timo Alexander, Fehrenbach, Uli, Gebauer, Bernhard, Haubold, Johannes, Zensen, Sebastian, Kim, Moon-Sung, Eisenblätter, Michel, Diallo, Thierno D., Bettinger, Dominik, Steinle, Verena, Chang, De-Hua, Zopfs, David, Pinto dos Santos, Daniel, and Kloeckner, Roman
- Subjects
CHEMOEMBOLIZATION ,HEPATOCELLULAR carcinoma ,MULTIVARIATE analysis ,REGRESSION analysis ,PROGNOSIS ,OVERALL survival - Abstract
Objectives: Recently, several scoring systems for prognosis prediction based on tumor burden have been promoted for patients with hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE). This multicenter study aimed to perform the first head-to-head comparison of three scoring systems. Methods: We retrospectively enrolled 849 treatment-naïve patients with HCC undergoing TACE at six tertiary care centers between 2010 and 2020. The tumor burden score (TBS), the Six-and-Twelve score (SAT), and the Seven-Eleven criteria (SEC) were calculated based on the maximum lesion size and the number of tumor nodes. All scores were compared in univariate and multivariate regression analyses, adjusted for established risk factors. Results: The median overall survival (OS) times were 33.0, 18.3, and 12.8 months for patients with low, medium, and high TBS, respectively (p<0.001). The median OS times were 30.0, 16.9, and 10.2 months for patients with low, medium, and high SAT, respectively (p<0.001). The median OS times were 27.0, 16.7, and 10.5 for patients with low, medium, and high SEC, respectively (p<0.001). In a multivariate analysis, only the SAT remained an independent prognostic factor. The C-Indexes were 0.54 for the TBS, 0.59 for the SAT, and 0.58 for the SEC. Conclusion: In a direct head-to-head comparison, the SAT was superior to the TBS and SEC in survival stratification and predictive ability. Therefore, the SAT can be considered when estimating the tumor burden. However, all three scores showed only moderate predictive power. Therefore, tumor burden should only be one component among many in treatment decision making. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. Value of spectral detector computed tomography for the early assessment of technique efficacy after microwave ablation of hepatocellular carcinoma.
- Author
-
Reimer, Robert Peter, Hokamp, Nils Große, Niehoff, Julius, Zopfs, David, Lennartz, Simon, Heidar, Mariam, Wahba, Roger, Stippel, Dirk, Maintz, David, dos Santos, Daniel Pinto, and Wybranski, Christian
- Subjects
HEPATOCELLULAR carcinoma ,TOMOGRAPHY ,DETECTORS ,MICROWAVES ,CIRRHOSIS of the liver - Abstract
Objectives: To investigate whether virtual monoenergetic images (VMI) and iodine maps derived from spectral detector computed tomography (SDCT) improve early assessment of technique efficacy in patients who underwent microwave ablation (MWA) for hepatocellular carcinoma (HCC) in liver cirrhosis. Methods: This retrospective study comprised 39 patients with 49 HCC lesions treated with MWA. Biphasic SDCT was performed 7.7±4.0 days after ablation. Conventional images (CI), VMI and IM were reconstructed. Signal- and contrast-to-noise ratio (SNR, CNR) in the ablation zone (AZ), hyperemic rim (HR) and liver parenchyma were calculated using regions-of-interest analysis and compared between CI and VMI between 40–100 keV. Iodine concentration and perfusion ratio of HR and residual tumor (RT) were measured. Two readers evaluated subjective contrast of AZ and HR, technique efficacy (complete vs. incomplete ablation) and diagnostic confidence at determining technique efficacy. Results: Attenuation of liver parenchyma, HR and RT, SNR of liver parenchyma and HR, CNR of AZ and HR were significantly higher in low-keV VMI compared to CI (all p<0.05). Iodine concentration and perfusion ratio differed significantly between HR and RT (all p<0.05; e.g. iodine concentration, 1.6±0.5 vs. 2.7±1.3 mg/ml). VMI
50keV improved subjective AZ-to-liver contrast, HR-to-liver contrast, visualization of AZ margin and vessels adjacent to AZ compared to CI (all p<0.05). Diagnostic accuracy for detection of incomplete ablation was slightly higher in VMI50keV compared to CI (0.92 vs. 0.89), while diagnostic confidence was significantly higher in VMI50keV (p<0.05). Conclusions: Spectral detector computed tomography derived low-keV virtual monoenergetic images and iodine maps provide superior early assessment of technique efficacy of MWA in HCC compared to CI. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
8. Immunonutritive Scoring in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Prognostic Nutritional Index or Controlling Nutritional Status Score?
- Author
-
Müller, Lukas, Hahn, Felix, Mähringer-Kunz, Aline, Stoehr, Fabian, Gairing, Simon J., Foerster, Friedrich, Weinmann, Arndt, Galle, Peter R., Mittler, Jens, Pinto dos Santos, Daniel, Pitton, Michael B., Düber, Christoph, and Kloeckner, Roman
- Subjects
NUTRITIONAL status ,CHEMOEMBOLIZATION ,HEPATOCELLULAR carcinoma ,OVERALL survival ,PROGNOSIS ,LYMPHOCYTE count - Abstract
Objectives: The Prognostic Nutritional Index (PNI) and Controlling Nutritional Status (CONUT) score are immunonutritive scoring systems with proven predictive ability in various cancer entities, including hepatocellular carcinoma (HCC). We performed the first evaluation of the CONUT score for patients undergoing transarterial chemoembolization (TACE) and compared CONUT and PNI in the ability to predict median overall survival (OS). Methods: Between 2010 and 2020, we retrospectively identified 237 treatment-naïve patients with HCC who underwent initial TACE at our institution. Both scores include the albumin level and total lymphocyte count. The CONUT additionally includes the cholesterol level. Both scores were compared in univariate and multivariate regression analyses taking into account established risk factors. In a second step, a subgroup analysis was performed on BCLC stage B patients, for whom TACE is the recommended first-line treatment. Results: A high CONUT score and low PNI were associated with impaired median OS (8.7 vs. 22.3 months, p<0.001 and 6.8 vs. 20.1 months, p<0.001, respectively). In multivariate analysis, only the PNI remained an independent prognostic predictor (p=0.003), whereas the CONUT score lost its predictive ability (p=0.201). In the subgroup of recommended TACE candidates, both CONUT and PNI were able to stratify patients according to their median OS (6.6 vs. 17.9 months, p<0.001 and 10.3 vs. 22.0 months, p<0.001, respectively). Again, in the multivariate analysis, only the PNI remained an independent prognostic factor (p=0.012). Conclusion: Both scores were able to stratify patients according to their median OS, but only the PNI remained an independent prognostic factor. Therefore, PNI should be preferred when evaluating the nutritional status of patients undergoing TACE. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
9. Quantitative assessment of washout in hepatocellular carcinoma using MRI
- Author
-
Klöckner, Roman, Pinto Dos Santos, Daniel, Kreitner, Karl-Friedrich, Leicher-Düber, Anne, Weinmann, Arndt, Mittler, Jens, and Düber, Christoph
- Subjects
Liver Cirrhosis ,Cancer Research ,Oncology ,610 Medical sciences ,Liver Neoplasms ,610 Medizin ,Genetics ,Hepatocellular Carcinoma ,Magnetic Resonance Imaging ,Research Article ,Decision Support Techniques - Abstract
Background Arterial hyperenhancement and washout on computed tomography and magnetic resonance imaging (MRI) are described by all major guidelines as specific criteria for non-invasive diagnosis of hepatocellular carcinoma (HCC). However, publications on the quantitative assessment of washout in MRI are lacking. Therefore, we evaluated a method for quantitatively measuring and defining washout in MRI in order to determine a cutoff value that allows objective HCC diagnosis. Methods We analyzed all patients who underwent liver transplantation for cirrhosis or liver resection for HCC at our institution between 2003 and 2014. Washout was quantitatively investigated by placing a 25-mm2 region of interest (ROI) over each nodule and two 25-mm2 ROIs over adjacent liver parenchyma. The percentage signal ratio (PSR = 100 × ratio of signal intensity of adjacent liver to that of the lesion) was calculated for each series in both groups. Accordingly, this quantitative measurement was compared to a qualitative approach. Results A total of 16 hypervascularized non-HCC nodules and 69 HCC nodules were identified. Interobserver reliability was reasonably good for the measurement of PSRs and readers showed a substantial agreement for the qualitative assessment. In the HCC group, the median PSR was 116.2 at equilibrium and 112.9 in the delayed phase. In the non-HCC group, the median PSR was 93.8 at equilibrium and 96.0 in the delayed phase. Receiver operating characteristic analysis indicated areas under the curve of 0.902 (p
- Published
- 2016
10. Predicting survival after transarterial chemoembolization for hepatocellular carcinoma using a neural network: A Pilot Study.
- Author
-
Mähringer‐Kunz, Aline, Wagner, Franziska, Hahn, Felix, Weinmann, Arndt, Brodehl, Sebastian, Schotten, Sebastian, Hinrichs, Jan B., Düber, Christoph, Galle, Peter R., Pinto dos Santos, Daniel, and Kloeckner, Roman
- Subjects
CHEMOEMBOLIZATION ,HEPATOCELLULAR carcinoma ,ARTIFICIAL neural networks ,PILOT projects ,RECEIVER operating characteristic curves - Abstract
Background and aims: Deciding when to repeat and when to stop transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC) can be difficult even for experienced investigators. Our aim was to develop a survival prediction model for such patients undergoing TACE using novel machine learning algorithms and to compare it to conventional prediction scores, ART, ABCR and SNACOR. Methods: For this retrospective analysis, 282 patients who underwent TACE for HCC at our tertiary referral centre between January 2005 and December 2017 were included in the final analysis. We built an artificial neural network (ANN) including all parameters used by the aforementioned risk scores and other clinically meaningful parameters. Following an 80:20 split, the first 225 patients were used for training; the more recently treated 20% were used for validation. Results: The ANN had a promising performance at predicting 1‐year survival, with an area under the ROC curve (AUC) of 0.77 ± 0.13. Internal validation yielded an AUC of 0.83 ± 0.06, a positive predictive value of 87.5% and a negative predictive value of 68.0%. The sensitivity was 77.8% and specificity 81.0%. In a head‐to‐head comparison, the ANN outperformed the aforementioned scoring systems, which yielded lower AUCs (SNACOR 0.73 ± 0.07, ABCR 0.70 ± 0.07 and ART 0.54 ± 0.08). This difference reached significance for ART (P <.001); for ABCR and SNACOR significance was not reached (P =.143 and P =.201). Conclusions: Artificial neural networks could be better at predicting patient survival after TACE for HCC than traditional scoring systems. Once established, such prediction models could easily be deployed in clinical routine and help determine optimal patient care. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
11. Extent of portal vein tumour thrombosis in patients with hepatocellular carcinoma: The more, the worse?
- Author
-
Mähringer‐Kunz, Aline, Steinle, Verena, Düber, Christoph, Schotten, Sebastian, Graafen, Dirk, Kloeckner, Roman, Galle, Peter R., Weinmann, Arndt, Koch, Sandra, Schmidtmann, Irene, Hinrichs, Jan B., and Pinto dos Santos, Daniel
- Subjects
PORTAL vein ,HEPATOCELLULAR carcinoma ,CROSS-sectional imaging ,THROMBOSIS ,MAGNETIC resonance imaging - Abstract
Background & Aims: Portal vein tumour thrombosis (PVTT) has a significant impact on the prognosis of patients with hepatocellular carcinoma (HCC). The degree of PVTT varies from sub‐/segmental invasion to complete occlusion of the main trunk. Aim of this study was to evaluate whether the degree of PVTT correlates with prognosis. Methods: A total of 1317 patients with HCC treated at our tertiary referral centre between January 2005 and December 2016 were included. PVTT was diagnosed by contrast‐enhanced computed tomography or magnetic resonance imaging. The extent of PVTT was documented according to the Liver Cancer Study Group of Japan classification: Vp0 = no PVTT, Vp1 = segmental portal vein invasion, Vp2 = right anterior/posterior portal vein, Vp3 = right/left portal vein and Vp4 = main trunk. Median overall survival (OS) was calculated for each group. Results: Portal vein tumour thrombosis was present in 484 (36.8%) patients. Median OS without PVTT was 35.7 months, significantly longer than in patients with PVTT (7.2 months, P < 0.001). The patients with PVTT were subclassified as follows: 103 Vp1, 87 Vp2, 143 Vp3 and 151 Vp4. The corresponding median OS yielded 14.6, 9.4, 5.8 and 4.8 months for Vp1‐Vp4, respectively (P < 0.001). Conclusions: Portal vein tumour thrombosis in patients with HCC is associated with a dismal prognosis. The results indicate an association between the extent of PVTT and OS. However, the extent of PVTT is not that decisive, as even minor PVTT leads to a very poor prognosis. Therefore, meticulous evaluation of cross‐sectional imaging is crucial for the clinical management of patients with HCC. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
12. Immunonutritive Scoring for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Evaluation of the CALLY Index.
- Author
-
Müller, Lukas, Hahn, Felix, Mähringer-Kunz, Aline, Stoehr, Fabian, Gairing, Simon Johannes, Michel, Maurice, Foerster, Friedrich, Weinmann, Arndt, Galle, Peter Robert, Mittler, Jens, Pinto dos Santos, Daniel, Pitton, Michael Bernhard, Düber, Christoph, and Kloeckner, Roman
- Subjects
C-reactive protein ,ALBUMINS ,INFLAMMATION ,MULTIVARIATE analysis ,CHEMOEMBOLIZATION ,RETROSPECTIVE studies ,REGRESSION analysis ,CANCER patients ,RISK assessment ,LYMPHOCYTES ,DESCRIPTIVE statistics ,SURVIVAL analysis (Biometry) ,HEPATOCELLULAR carcinoma ,NUTRITIONAL status - Abstract
Simple Summary: The novel CRP–albumin–lymphocyte (CALLY) index has been identified as a highly predictive tool for stratification of patients with hepatocellular carcinoma (HCC) who have undergone tumor resection. This study aimed to validate the predictive ability of the CALLY index in patients with HCC treated with transarterial chemoembolization (TACE). The CALLY index was an independent prognostic predictor for overall survival. However, the CALLY index was not superior to other immunonutritive and inflammation scoring systems in predicting the median OS, although all of the individual parameters of the CALLY index were predictive for the median OS. Thus, future studies should re-evaluate the mathematical calculation of the index for patients with HCC undergoing TACE. The novel CRP–albumin–lymphocyte (CALLY) index is an improved immunonutritive scoring system, based on serum C-reactive protein (CRP), serum albumin, and the lymphocyte count. It has shown promise as a prognostic index for patients with hepatocellular carcinoma (HCC) undergoing resections. This study evaluated the prognostic ability of the CALLY index for patients with HCC undergoing transarterial chemoembolization (TACE). We retrospectively identified 280 treatment-naïve patients with HCC that underwent an initial TACE at our institution, between 2010 and 2020. We compared the CALLY index to established risk factors in univariate and multivariate regression analyses for associations with median overall survival (OS). A low CALLY score was associated with low median OS (low vs. high CALLY: 9.0 vs. 24.0 months, p < 0.001). In the multivariate analysis, the CALLY index remained an independent prognostic predictor (p = 0.008). Furthermore, all factors of the CALLY index reached significance in univariate and in-depth multivariate analyses. However, the concordance index (C-index) of the CALLY index (0.60) was similar to the C-indices of established immunonutritive and inflammation scoring systems (range: 0.54 to 0.63). In conclusion, the CALLY index showed promise as a stratification tool for patients with HCC undergoing TACE. Notably, the CALLY index was not superior to other immunonutritive and inflammation scoring systems in predicting the median OS. Thus, future studies should re-evaluate the mathematical calculation of the index, particularly the contributions of individual parameters. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
13. Refining Prognosis in Chemoembolization for Hepatocellular Carcinoma: Immunonutrition and Liver Function.
- Author
-
Müller, Lukas, Hahn, Felix, Mähringer-Kunz, Aline, Stoehr, Fabian, Gairing, Simon Johannes, Foerster, Friedrich, Weinmann, Arndt, Galle, Peter Robert, Mittler, Jens, Pinto dos Santos, Daniel, Pitton, Michael Bernhard, Düber, Christoph, and Kloeckner, Roman
- Subjects
LUNG physiology ,SURVIVAL ,TIME ,CHEMOEMBOLIZATION ,RETROSPECTIVE studies ,RISK assessment ,SERUM albumin ,CANCER patients ,IMMUNONUTRITION diet ,DESCRIPTIVE statistics ,HEPATOCELLULAR carcinoma ,NUTRITIONAL status ,BILIRUBIN - Abstract
Simple Summary: The combination of the albumin-bilirubin (ALBI) grading and the Prognostic Nutritional Index (PNI) offers potential as a highly predictive tool for patients with hepatocellular carcinoma (HCC). The present study evaluated this combination firstly for patients undergoing transarterial chemoembolization (TACE). Both the ALBI grade and PNI were strong independent predictors of survival. However, the combination of the two scores allowed for even more precise predictions. In addition, this new ALBI-PNI outperformed several established scoring systems. Thus, the easy-to-calculate ALBI-PNI may be a promising stratification tool for patients with HCC undergoing TACE in daily clinical routine. A combination of albumin-bilirubin (ALBI) grading and the Prognostic Nutritional Index (PNI) was identified recently as a highly predictive tool for patients with hepatocellular carcinoma (HCC) undergoing tumor ablation. The present study evaluated this combination in patients undergoing transarterial chemoembolization (TACE). Between 2010 and 2020, 280 treatment-naïve patients were retrospectively identified. The influence of ALBI grade, PNI and the novel ALBI-PNI on the median overall survival (OS) was assessed. In the next step, the prognostic ability of the combined approach was compared to established scoring systems. Both ALBI grade 2−3 and a low PNI were highly predictive for median OS (ALBI grade 1–3: 39.0 vs. 16.3 vs. 5.4 months, p < 0.001; high vs. low PNI: 21.4 vs. 7.5, p < 0.001). The combination of both resulted in a median OS of 39.0, 20.1, 10.3, and 5.4 months (p < 0.001). With a Concordance Index (C-Index) of 0.69, ALBI-PNI outperformed each individual score (ALBI 0.65, PNI 0.64) and was also better than BCLC, HAP, mHAP-II, and the Six-and-Twelve score (C-Indices 0.66, 0.60, 0.59, and 0.55). Thus, the easy-to-calculate ALBI-PNI may be a promising stratification tool for patients with HCC undergoing TACE, reflecting both immunonutritive status and liver function. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.